Posted by Michael Wonder on 27 Jan 2017
Institute for Clinical and Economic Review releases evidence report on disease-modifying therapies for multiple sclerosis, including daclizumab and ocrelizumab
26 January 2017 - Report finds alemtuzumab represents best long-term cost-effectiveness; prices for most drugs not well-aligned with added value for patients. Stakeholder collaboration needed to improve access for patients.
The Institute for Clinical and Economic Review (ICER) has released an evidence report assessing the comparative clinical effectiveness and value of 15 disease-modifying therapies (DMTs) for treatment of relapsing-remitting and primary-progressive multiple sclerosis. This Evidence Report will be the subject of the upcoming public meeting of the California Technology Assessment Forum on February 16, 2017.
The analyses showed that when compared to supportive care, all of the DMTs under review improved health outcomes related to delayed disability and prevention of relapses. The DMTs showed mixed results in in how well they worked compared to generic glatiramer acetate, a commonly used treatment in current practice. While evidence on clinical effectiveness demonstrated improvements on key outcomes, cost-effectiveness analyses showed that current prices for nearly all drugs reviewed are not aligned with the long-term added value for patients.
